基础胰岛素/胰高糖素样肽1受体激动剂固定比例复方制剂的药物作用机制及临床研究进展  

Fixed-ratio combination of basal insulin and GLP-1 receptor agonists:mechanism and clinical trials progress

作　　者：肖建中[1] XIAO Jianzhong(Department of Endocrinology,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing 102218.China)

机构地区：[1]清华大学附属北京清华长庚医院内分泌科,102218

出　　处：《中国糖尿病杂志》2024年第1期70-75,共6页Chinese Journal of Diabetes

摘　　要：T2DM是一种病理生理机制复杂的进展性疾病,随DM病程进展需要不同作用机制的降糖药物,纠正多重病理生理缺陷来控制BG。基础胰岛素/胰高糖素样肽1受体激动剂(GLP-1RA)固定比例复方制剂(FRC)每日1次注射可同时给予2种机制互补的降糖药物,纠正T2DM已知病理生理缺陷中的7种,可全面有效地控制BG。本文对基础胰岛素/GLP-1RA的FRC药物作用机制及国内外临床研究进展作一回顾性讨论,为临床医师提供参考。Type 2 diabetes mellitus(T2DM)is a progressive disease that has a complex pathophysiology mechanism.As T2DM progresses,a combination of antidiabetic drugs with multiple mechanisms of action may often be required to correct the multiple pathophysiological defects to achieve glycemic control.The basal insulin/glucagon-like peptide-1 receptor agonist(GLP-1RA)fixed-ratio combination(FRC)is a once-daily injectable treatment that allows simultaneous administration of two antidiabetic drugs with complementary mechanisms,addressing seven of eight key defects in T2DM to achieve glycemic control comprehensively and effectively.This article will discuss the mechanism of action and clinical trials progress at home and abroad of basal insulin/GLP-1RA FRC,only to provide reference information for clinicians.

关 键 词：基础胰岛素 GLP-1受体激动剂 固定比例复方制剂 作用机制 

分 类 号：R587.1[医药卫生—内分泌]